The 2023 Standards of Care in Diabetes ADA guidelines advocate for GLP-1 RA or SGLT-2i use in patients with T2DM and ASCVD or CKD to reduce the risk of macro- and microvascular complications in this category of patients [4]. The gene discussed is GCG; the disease is type 2 diabetes mellitus.